Working... Menu

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01005979
Recruitment Status : Terminated (Slow Accrual)
First Posted : November 2, 2009
Last Update Posted : August 13, 2014
Celgene Corporation
Information provided by (Responsible Party):
Christopher R. Flowers, Emory University

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : October 2012
  Study Completion Date : No date given